報價延遲最少15分鐘:2026/01/08 16:14 EST
盤後時段
|
||||
|
1.15 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.15
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.36/-0.05
|
|
企業價值
37.23M
|
| 資產負債 |
|
每股賬面淨值
0.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
43.00K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. |
